INTRODUCTION
The tocopherols are important agents in preventing cellular oxidative damage, and are postulated to protect against the development of cancer and other aging-related diseases (1, 2) . Although α-tocopherol (αT) has the highest level of vitamin E bioactivity amongst the tocopherols (3) and, consequently, has been the target of most animal and epidemiologic research over the years, more recent findings have pointed to the other tocopherols, particularly γ-tocopherol (γT), as playing significant roles in inhibiting the development of cancer in animal models (2) . Epidemiological evidence, while limited, also suggests an inverse association of γT with certain cancers (4, 5) and heart disease (6) . γT has been identified as a key cellular antioxidant that specifically blocks damage to cells resulting from the enzymatic production of nitric oxide (NO), a mediator of inflammation through its oxidation products (7, 8) . Conversely, αT appears to be a primary reactant against cellular oxygen-based oxidants, but lacks anti-inflammatory activity (9). Together the two forms of tocopherol protect cells from the major forms of endogenous oxidative assault. The assumption that serum tocopherol levels reflect dietary intake is valid only in cases of severe deficiency or heavy supplement use (10); hence, the physiologic determinants of serum levels of the tocopherols may be key to elucidating their potential functions for either reducing/promoting disease or serving as markers of risk. In particular, serum levels of γT appear to be unrelated to dietary intake and may reflect to a large extent the level of chronic inflammation as suggested by its positive associations with circulating C-reactive protein and urinary isoprostane (11) , thereby complicating the epidemiologic interpretation of its associations with diseases. Chai 4 Vitamin D is associated with lower risk for cancer, primarily colorectal (12, 13) , cardiovascular disease (14) , and all-cause mortality (15 3 ), and γT were significantly inversely associated with one another and in turn associated with all-cause mortality (11) . In that same study, a positive association of circculating αT with 25[OH]D was observed. It was hypothesized that deficiency of vitamin D may lead to a state of chronic inflammation resulting in elevated γT levels which protect against NO-mediated damage, thereby compensating against some of the deleterious consequences of vitamin D deficiency. However, in previous studies (17, 18) , it was also observed that both body mass index (BMI) and leptin (an adipocytokine produced predominantly by white adipose tissue) were inversely associated with serum 
METHODS

Study population and protocol:
This study utilized stored serum samples from a previous pilot, randomized, The placebo was free of calcium, magnesium, vitamin D, and chelating agents.
Additional details on the rationale for the doses and forms of calcium and vitamin D 3 supplements were described previously (24).
The treatment period was 6 months, and participants attended follow-up visits at 2 and 6 months after randomization and were contacted by telephone between the second and final follow-up visits. Pill-taking adherence was assessed by questionnaire, interview, and pill count. Participants were instructed to remain on their usual diet and not take any nutritional supplements not in use on entry into the study. Blood was collected at baseline (randomization) and at study completion (6-month follow-up), and diet was assessed with a semi-quantitative food frequency questionnaire (25). A total of 85 subjects (21-22 per group) completing the study with blood samples at baseline and at six months were available for analysis and utilized in the current study. effects, we also calculated proportional treatment effects, defined as (absolute treatment effect / treatment group baseline) x 100% (e.g., a proportional effect of 56% would mean a 56% increase in the active treatment group relative to the placebo group). Because the treatment groups were balanced on potentially influential factors (participant characteristics and dietary intakes of certain nutrients) at baseline, no adjustment was made for other covariates in the primary intent-to-treat analyses. Spearman correlation was used to assess the associations between analyte levels. SAS software (SAS Institute, Chai 9
Cary, North Carolina) was used for analyses. All tests were two sided, and P < 0.05 was considered statistically significant.
RESULTS
Characteristics of study participants
The four treatment groups did not differ significantly with respect to participant characteristics measured at baseline (Table 1 , based on a total of 92 originally randomized subjects). The mean age of participants was 60.5 ± 7.9 (SD) years, 64%
were men, 71% were white, 88% were current non-smokers, and 82% were overweight or γT (r = -0.31, P = 0.004) but were not significantly correlated with αT (r = 0.12, P = 0.29). Serum αT and γT levels were not significantly correlated with each other at baseline (r = -0.10, P = 0.38).
Chai 11
Mean serum levels of αT, γT, retinol, and leptin for each group at baseline and after six months supplementation are shown in Table 3 . While both vitamin D 3 intervention groups had lower γT levels after six months supplementation with vitamin D 3 relative to baseline, the absolute treatment effect, which also factors in changes in the placebo group, were not statistically significant. Serum αT and γT levels decreased by 14% (P = 0.04) and 19% (P = 0.14), respectively, in the calcium plus vitamin D 3 group relative to placebo when analyzed by absolute treatment effect. There also appeared to be a trend for decreasing serum γT levels as indicated by the relative treatment effects (calcium group, -3%, P = 0.85; vitamin D 3 group, -8%, P = 0.57; calcium plus vitamin D 3
group, -19%, P = 0.14). As shown in Figure 1 Although lower retinol levels were observed in supplemental D 3 +/-calciumtreated subjects (Table 3) , slightly higher retinol levels were observed in subjects treated with vitamin D 3 alone, indicating no consistent effect of vitamin D 3 supplementation on retinol. In the current study 82% of study participants were overweight or obese and their weight remained constant over the 6-month experimental period (mean BMI: baseline, 30.1 ± 6.1 kg/m 2 ; 6 months, 30.2 ± 6.2 kg/m 2 ). Baseline leptin values were highly correlated with BMI (r = 0.67, P < 0.0001) and significantly correlated with γT (r = 0.24, P = 0.03). No significant changes in leptin levels ( (11) . Lower αT and a trend towards lower γT were observed after D 3 supplementation (Table 3 and Figure 1) ; however, the sample size was too small to detect the estimated absolute treatment effect on γT. 
Chai 14
The previously reported positive correlation of serum αT and 25[OH]D levels (11) was also observed in the baseline levels of the participants in the present study (although it was not statistically significant); however, vitamin D 3 supplementation in the current study clearly did not increase circulating αT, as αT levels were significantly lower after supplementation in the calcium plus vitamin D 3 group. The positive association for αT in the previous study may have been due to the multi-ethnic population studied (11) and/or the confounding effects of αT supplementation in that population. This effect was not tested in the current study, as there was no significant correlation between αT and γT levels at baseline and no αT was provided as a supplement. Another explanation may be that vitamin D deficiency does indeed cause both tocopherols to rise but αT is depleted to a greater extent because of the increased oxidation associated with an inflammatory state resulting from vitamin D deficiency. Evidence for such a mechanism is provided in cell culture studies where it was observed that inducing oxidative stress causes γT to rise in relation to αT; however, if NO synthesis and a corresponding oxidative assault are inhibited, then levels of both tocopherols would rise in response to the inflammatory trigger (34). In a separate analysis of the subjects used in the current study (35), biomarkers of inflammation were observed to be lower in vitamin D 3 -treated subjects, consistent with the hypothesis that tocopherols were lower as a result of decreased inflammation. The potentially interactive effects of calcium with vitamin D 3 seen for tocopherols in the present study are intriguing and warrant further investigation to determine the mechanism of action.
Previous reports indicated that serum 25[OH]D levels were inversely associated
with BMI (17, 18) , suggesting a possible influence of obesity and its associated effects on Chai 15 leptin on metabolic pathways of vitamin D and /or its precursors. In the current study the majority (82%) of study participants were overweight or obese and their weight remained constant over the 6-month experimental period (mean BMI: baseline, 30.1 ± 6.1 kg/m 2 ; 6 months, 30.2 ± 6.2 kg/m 2 ), as did serum leptin levels (Table 3) The strengths of the present study included the randomized, double-blind, placebo-controlled trial design; high protocol adherence by study participants; and that it is the first study to examine both the independent and combined effects of calcium and vitamin D 3 on serum antioxidant micronutrients and specific vitamin D metabolites.
Limitations of the current study included the relatively small sample size in each treatment group and the high BMI levels of most subjects. However, the findings from this pilot study are nevertheless novel, consistent with previous observational and cell culture data that point to a possible causal relationship between vitamin D deficiency and circulating tocopherol levels, and provide important data for the future designs of studies to assess the effects of vitamin D 3 supplementation on biochemical and nutritional parameters. ]. c Proportional treatment (Rx) effect = (absolute treatment effect / treatment group baseline) x 100% (e.g., a proportional effect of 55% would mean that a 55% increase in the active treatment group relative to the placebo group). d P value for difference between each active treatment group and the placebo group from repeated measures MIXED model. Table 3 . Serum levels of α-tocopherol, γ-tocopherol, retinol, and leptin at baseline and after 6 months of treatment. c Proportional treatment (Rx) effect = (absolute treatment effect / treatment group baseline) x 100% (e.g., a proportional effect of 55% would mean that a 55% increase in the active treatment group relative to the placebo group). d P value for difference between each active treatment group and the placebo group from repeated measures MIXED model.
